JinekM, ChylinskiK, FonfaraI, et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337:816–821. DOI: 10.1126/science.1225829.
2.
GasiunasG, BarrangouR, HorvathP, et al.Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. 2012; 109:E2579–E2586. DOI: 10.1073/pnas.1208507109.
3.
FrangoulH, AltshulerD, CappelliniMD, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021; 384:252–260. DOI: 10.1056/NEJMoa2031054.
4.
GillmoreJD, GaneE, TaubelJ, et al.CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021; 385:493–502. DOI: 10.1056/NEJMoa2107454.
5.
StadtmauerEA, FraiettaJA, DavisMM, et al.CRISPR-engineered T cells in patients with refractory cancer. Science, 2020; 367:eaba7365. DOI: 10.1126/science.aba7365.
6.
UrnovFD. Genome editing B.C. (before CRISPR): lasting lessons from the “old testament.”. CRISPR J. 2018; 1:34–46. DOI: 10.1089/crispr.2018.29007.fyu.
7.
KanterJ, WaltersMC, KrishnamurtiL, et al. Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2117175.
8.
AkincA, MaierMA, ManoharanM, et al.The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019; 14:1084–1087. DOI: 10.1038/s41565-019-0591-y.
9.
WilsonR. Outsmarting delivery barriers in vivo: base editing via next-generation virus-like particles GENBiotechnology. 2022;1:30–32. DOI: 10.1089/genbio.2022.29012.rwi.
10.
BursteinD, HarringtonLB, StruttSC, et al.New CRISPR-Cas systems from uncultivated microbes. Nature. 2017; 542:237–241. DOI: 10.1038/nature21059.
11.
NishimasuH, ShiX, IshiguroS, et al.Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science. 2018; 361:1259–1262. DOI: 10.1126/science.aas9129.
12.
MillerSM, WangT, RandolphPB, et al.Continuous evolution of SpCas9 variants compatible with non-G PAMs. Nat Biotechnol. 2020; 38:471–481. DOI: 10.1038/s41587-020-0412-8.
13.
KomorAC, KimYB, PackerMS, et al.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533:420–424. DOI: 10.1038/nature17946.
14.
DaviesK, KomorAC, GaudelliNM. The beginning of base editing: an interview with Alexis C. Komor and Nicole M. Gaudelli. CRISPR J., 2019; 2:81–90. DOI: 10.1089/crispr.2019.29050.kda.
15.
ZhaoD, LiJ, LiS, et al.Glycosylase base editors enable C-to-A and C-to-G base changes. Nat Biotechnol. 2021; 39:35–40. DOI: 10.1038/s41587-020-0592-2.
16.
AnzaloneAV, RandolphPB, DavisJR, et al.Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019; 576:149–157. DOI: 10.1038/s41586-019-1711-4.
17.
VoPLH, RondaC, KlompeSE, et al.CRISPR RNA-guided integrases for high-efficiency, multiplexed bacterial genome engineering. Nat Biotechnol. 2021; 39:480–489. DOI: 10.1038/s41587-020-00745-y.
